Literature DB >> 32507446

A pilot study of the effect of curcumin on epigenetic changes and DNA damage among patients with non-alcoholic fatty liver disease: A randomized, double-blind, placebo-controlled, clinical trial.

Mitra Hariri1, Ali Gholami2, Seyed Reza Mirhafez3, Mohammad Bidkhori3, Amirhosein Sahebkar4.   

Abstract

BACKGROUND: The enhancement of oxidative stress in non-alcoholic fatty liver disease (NAFLD) patients may cause mutation in DNA by deamination of cytosine to 5-hydroxyuracil or uracil. This study aimed to discover the effects of curcumin on NAFLD progress, DNA damage caused by oxidative stress, and promoter methylation of mismatch repair enzymes.
MATERIAL AND METHODS: in this study, 54 NAFLD patients were randomly devided into two groups, according to a double blind parallel design either phytosomal curcumin (250 mg/day) or placebo for 8 weeks. Fasting blood samples and anthropometric measures were taken twice, once at the baseline and once at the end of the study. Promoter methylation and 8-hydroxy-2' -deoxyguanosine (8-OHdG) concentration as DNA damage mediator were measured by restriction enzymes and enzyme-linked immunosorbent assay, respectively. RESULT: Analysis was performed on 44 patients. According to our between groups analysis, curcumin significantly reduced the methylation in MutL homolog 1 (MLH1) and MutS homolog 2 (MSH2) promoter regions. The within-group comparison revealed that anthropometric variables significantly decreased. However, the result of the between groups comparison indicated no significant changes in the anthropometric variables except for BMI. Liver enzymes and 8-OHdG did not significantly change at the end of the study, neither in curcumin group nor in placebo group.
CONCLUSION: Curcumin might be able to reduce the risk of mismatch base pair in DNA among the NAFLD patients. However, it did not change the DNA damage mediator and liver enzymes. For confirming these results, more studies with longer duration, more numbers of examined genes, higher dose of curcumin, and larger sample size are required.
Copyright © 2020 Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  Epigenetic; Liver enzymes; Non-alcoholic fatty liver; Promoter methylation

Year:  2020        PMID: 32507446     DOI: 10.1016/j.ctim.2020.102447

Source DB:  PubMed          Journal:  Complement Ther Med        ISSN: 0965-2299            Impact factor:   2.446


  5 in total

Review 1.  Curcuminoids for Metabolic Syndrome: Meta-Analysis Evidences Toward Personalized Prevention and Treatment Management.

Authors:  Agustina Dwi Retno Nurcahyanti; Fonny Cokro; Martha P Wulanjati; Mona F Mahmoud; Michael Wink; Mansour Sobeh
Journal:  Front Nutr       Date:  2022-06-09

Review 2.  Curcumin May Prevent Basement Membrane Disassembly by Matrix Metalloproteinases and Progression of the Bladder Cancer.

Authors:  Paweł Wroński; Stanisław Wroński; Marcin Kurant; Bartosz Malinowski; Michał Wiciński
Journal:  Nutrients       Date:  2021-12-23       Impact factor: 5.717

3.  Investigation of the Effect of Curcumin on Protein Targets in NAFLD Using Bioinformatic Analysis.

Authors:  Ali Mahmoudi; Alexandra E Butler; Muhammed Majeed; Maciej Banach; Amirhossein Sahebkar
Journal:  Nutrients       Date:  2022-03-22       Impact factor: 5.717

4.  Efficacy and safety of dietary polyphenol supplementation in the treatment of non-alcoholic fatty liver disease: A systematic review and meta-analysis.

Authors:  Kailin Yang; Junpeng Chen; Tianqing Zhang; Xiao Yuan; Anqi Ge; Shanshan Wang; Hao Xu; Liuting Zeng; Jinwen Ge
Journal:  Front Immunol       Date:  2022-09-09       Impact factor: 8.786

5.  The efficacy of novel metabolic targeted agents and natural plant drugs for nonalcoholic fatty liver disease treatment: A PRISMA-compliant network meta-analysis of randomized controlled trials.

Authors:  Jingwen Zhou; Yidi Chen; Jun Yu; Tianci Li; Ziyu Lu; Yan Chen; Xiaolong Zhang; Fang Ye
Journal:  Medicine (Baltimore)       Date:  2021-03-26       Impact factor: 1.817

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.